This article has been cited by
1Analgesic effects evoked by a CCR2 antagonist or an anti-CCL2 antibody in inflamed mice
María Llorián-Salvador,Marta Pevida,Sara González-Rodríguez,Ana Lastra,María-Teresa Fernández-García,Agustín Hidalgo,Ana Baamonde,Luis Menéndez
Fundamental & Clinical Pharmacology.2016;30(3)235
[DOI]
2Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines
Mohaned Ahmed,Haneen A. Basheer,Jose M. Ayuso,Djevdet Ahmet,Marco Mazzini,Roshan Patel,Steven D. Shnyder,Victoria Vinader,Kamyar Afarinkia
Scientific Reports.2017;7(1)235
[DOI]
3Chemokine (C-C motif) Receptor 5 Is an Important Pathological Regulator in the Development and Maintenance of Neuropathic Pain
Katsuyuki Matsushita,Hidetoshi Tozaki-Saitoh,Chinami Kojima,Takahiro Masuda,Makoto Tsuda,Kazuhide Inoue,Sumio Hoka
Anesthesiology.2014;120(6)1491
[DOI]
4Chemokine receptors on T cells in multiple sclerosis
Wakiro Sato
Clinical and Experimental Neuroimmunology.2014;5(2)162
[DOI]
5Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8
Mami Noda,Daichi Tomonaga,Kota Kitazono,Yusaku Yoshioka,Jiadai Liu,Jean-Philippe Rousseau,Richard Kinkead,Michael R. Ruff,Candace B. Pert
Neurochemistry International.2018;119(2)184
[DOI]
6Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development
Valérie Bégin-Lavallée,Élora Midavaine,Marc-André Dansereau,Pascal Tétreault,Jean-Michel Longpré,Ashley M Jacobi,Scott D Rose,Mark A Behlke,Nicolas Beaudet,Philippe Sarret
Molecular Pain.2016;12(2)174480691665396
[DOI]
7Microglia-neuron interactions in the models of neuropathic pain
Hidetoshi Tozaki-Saitoh,Makoto Tsuda
Biochemical Pharmacology.2019;169(2)113614
[DOI]
  Feedback 
  Subscribe